Amatica started as a patient community project, built around a belief that patients with complex diseases such as Long COVID and ME/CFS need precision medicine that matches treatments to biological signatures to improve unpredictable treatment outcomes.
The problem
Currently, millions of patients are left without viable care and are forced to experiment with their own health, taking off-label medications in hope of a positive response. While a minority of patients find treatments they benefit from, far more have no response and some are left permanently worse. Our team has experienced this ‘treatment roulette’ first hand.
As patients ourselves, we didn’t have years to wait for small clinical trials that average patients together to advance.
Our solution
We believe that the future of care will be shaped by precision medicine and individual agency.
We offer patients the next generation of biological tests, combined with deep characterisation of disease profiles and states.
We are building the richest multimodal dataset, designed for analysis using state-of-the-art machine learning and AI, with the aim of improving the lives of millions of patients faster than was previously possible.
Today we're taking our biggest step towards our goal. We've closed a multi-million dollar seed funding round with the goal of building the leading precision medicine company in chronic neuroimmune disease, starting with Long COVID and ME/CFS.
Building the team
After volunteering since our launch in 2025, our team is now full-time, and we're expanding. We're hiring leading computational biologists, data scientists and machine learning researchers to work on one of the richest patient datasets in this field. If that sounds like you, see our
open roles.
Making the test affordable
Without the ability to subsidise cost, our test was out of reach for many. We're now putting a significant share of our funding into subsidising it.
From today, our RNA test costs $495. We believe this can accelerate building the data scale needed to make an impact in patient care. This subsidised price is available to the first 500 new patients who consent to research.
Our best analysis yet
One of Amatica’s goals is to make the richest and most complex biological data understandable to everyone.
Every patient now receives an intuitive summary, built from personalised pathway analysis and clustering across the 60,000+ gene expression measurements from your RNA sequencing.
Your report provides insight into the states of key biological systems (including mitochondrial function, immune states, vascular function and inflammatory signalling) and where your profile sits compared with other patients and reference controls.
As our researchers identify new subgroups and associations, those analyses are added to your portal at no additional cost, so you can see where you fit as the science develops.
Building a multi-omic dataset
We're building a multi-omic dataset that brings different types of biological information together to power state-of-the-art machine learning research.
With consent, every new patient's blood draw will also provide five additional sample types, banked for future proteomic, metabolomic, genomic, epigenomic and extracellular vesicle analysis. Our test today is RNA sequencing only. The banked samples mean future analyses can be run without another blood draw and data can be combined.
Proteomics will be added next as a paid add-on, with a 1,000-protein panel. Over time, we'll integrate these layers and apply machine learning and AI to find signatures linked to disease states and biological subgroups.
What we're seeing so far
Early analysis of our cohort points to shifts in B cell states, mitochondrial pathways, stress hormone responses and antiviral signalling. This builds on our preliminary classifier research covered in our
recent blog post.
Our existing patients
The people who supported Amatica at full price made all of this possible. We've set aside funds so every existing RNA patient who has consented to research receives a second longitudinal RNA test free. A second sample lets us see how biology changes over time and with disease states, and longitudinal data like this is some of the most valuable for research. Every existing patient also receives the new pathway and clustering analysis.
Blood collection and shipping
We’ve simplified blood collection. The blood draw is now included in the price rather than an extra cost, and no centrifuging or additional processing is required. We can connect you with our partner mobile phlebotomists and support every step of collection and shipping. In the US our partner phlebotomist will handle return shipping for you. RNA sequencing is now carried out by our new CLIA/CAP accredited lab partner in the US.
Our vision
As severely affected patients ourselves, we see advancing care as our only path to regaining our lives.
Next-generation tests, the maturation of precision medicine and the arrival of AI are converging. We believe this is the moment when decades of impasse in chronic disease care can be overcome.
Our model is designed to leverage this convergence to improve the lives of millions of patients within years, not decades.
Thank you to everyone who has been part of our mission so far and we are excited for this next phase
